JP3805900B2 - Antifungal agent and composition containing the same - Google Patents

Description

一般式（Ｉ）
（但し、式中Ｒ１はフッ素原子を含有する芳香族炭化水素基を表し、Ｒ２は炭素数１〜４のアルキル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【０００７】
【化１２】

一般式（ＩＩ）
（但し、式中Ｘはフッ素原子又はトリフルオロメチル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【０００８】
【発明の実施の形態】
（１）本発明の一般式（ＩＩＩ）及び／又一般式（ＩＶ）に表される化合物
本発明の一般式（ＩＩＩ）及び／又は一般式（ＩＶ）に表される化合物は、一般式（Ｉ）及び／又は一般式（ＩＩ）の化合物を製造する際の重要な反応中間体である。このものをヴィティヒ反応に付すことにより、本発明の一般式（Ｉ）乃至は一般式（ＩＩ）に表される化合物を製造することが出来る。本発明においては、一般式（ＩＩＩ）に表される化合物の内、側鎖を特定した一般式（ＩＶ）の化合物が特に好ましい。又、ハロゲン原子としては塩素原子が特に好ましい。又、この化合物は反応式１に示す如く、芳香族化合物乃至はそのハロゲン化物をルイス酸の存在下アセチル化ししかる後にこのアセチル基のメチルの水素原子をハロゲン原子で置換し、このものと対応するアミンとをアルカリ存在下、縮合する事により製造できる。これらの化合物は何れも文献未記載の新規化合物である。又、本発明のこの様な化合物として特に好ましいものは、２−［Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチルアミノ］−３’−（トリフルオロメチル）アセトフェノン（化合物４）、トランス−２−［Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）メチルアミノ］−３’−（トリフルオロメチル）アセトフェノン（化合物５）及び２−［Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチルアミノ］−２’，５’−ジフルオロアセトフェノン（化合物６）が挙げられる。
【０００９】
【化１３】

一般式（ＩＩＩ）
（但し、式中Ｒ１はフッ素原子を含有する芳香族炭化水素基を表し、Ｒ２は炭素数１〜４のアルキル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【００１０】
【化１４】

一般式（ＩＶ）
（但し、式中Ｘはフッ素原子又はトリフルオロメチル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【００１１】
【化１５】

（化合物４）
【００１２】
【化１６】

（化合物５）
【００１３】
【化１７】

（化合物６）
【００１４】
【化１８】

反応式１
（但し、式中Ｘはフッ素原子又はトリフルオロメチル基を表し、Ｒ３はπ電子を少なくとも６個有する炭化水素基を表す。）
【００１５】
（２）本発明の一般式（Ｉ）、一般式（ＩＩ）に表される化合物
本発明の一般式（Ｉ）、一般式（ＩＩ）に表される化合物は、上記一般式（ＩＩＩ）、一般式（ＩＶ）に表される化合物を、メチルトリフェニルホスホニウムブロミドとブチルリチウムで処理すること、即ち、ウィッティヒ反応に付すことにより得ることが出来る。本発明に於いて、一般式（Ｉ）で表される化合物の内、一般式（ＩＩ）で表される限定された化合物群が好ましい。更に、フッ素原子の含有形態としては、フッ素原子そのものを置換基に用いることやトリフルオロメチル基を置換基として用いることが好ましい。これはこの様な化合物群が優れた抗真菌活性を有するからである。この様な化合物を具体的に例示すれば、例えばＮ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物１）、トランス−Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物２）、Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−（２，５−ジフルオロフェニル）−２−プロペニルアミン（化合物３）等が例示できる。これらのものは、通常の方法に従って塩へと導くことが出来る。即ち、水系或いは非水系溶媒中で対応する酸を添加することにより塩とすることが出来る。本発明で好ましい塩の種類としては、例えば、塩酸、硫酸、燐酸、硝酸などの鉱酸塩、酢酸、シュウ酸、マレイン酸、フマル酸等の有機酸塩等が例示でき、この中では塩酸塩が特に好ましい。これは、安定性と経済性に優れるからである。かくして得られた一般式（Ｉ）、一般式（ＩＩ）に表される化合物及び／又はその塩は、優れた抗真菌作用を有するため、本発明の抗真菌剤として使用することが出来る。又、本発明の抗真菌剤は安全性にも優れるため、その投与経路は問わない。本発明の化合物の抗真菌剤としての投与量は、患者の状態や症状により異なるが、例えば、経口投与や注射による投与であれば、成人１日、１〜１００００ｍｇを１回乃至は数回に分けて投与するのが好ましく、皮膚外用剤であれば０．１〜１０重量％含有するものを適量塗布するのが好ましく、膣座剤であれば、０．１〜１０重量％含有する座剤を１回乃至は数回取り替えて投与するのが好ましい。
【００１６】
（３）本発明の医薬組成物
本発明の医薬組成物は、上記本発明の抗真菌剤を含有することを特徴とする。後記実施例に示す如く、本発明の抗真菌剤は優れた抗真菌作用を有するため、本発明の医薬組成物は、表在性真菌症や深在性真菌症の治療や悪化の予防、再発防止に大変有益である。本発明の医薬組成物としては、例えば、液剤、クリーム、軟膏などの皮膚外用剤、錠剤、カプセル剤、散剤などの経口製剤、注射剤、膣座剤等の剤形が好ましく例示できる。本発明の医薬組成物には、上記抗真菌剤以外に、通常医薬組成物で使用される任意成分を含有することが出来る。この様な任意成分としては、例えば、経口製剤や注射剤であれば、賦形剤、結合剤、被覆剤、滑沢剤、糖衣剤、崩壊剤、増量剤、矯味矯臭剤、乳化・可溶化・分散剤、安定剤、ｐＨ調整剤、等張剤等が例示でき、皮膚外用剤や膣座剤であれば、ワセリンやマイクロクリスタリンワックス等のような炭化水素類、ホホバ油やゲイロウ等のエステル類、牛脂、オリーブ油等のトリグリセライド類、セタノール、オレイルアルコール等の高級アルコール類、ステアリン酸、オレイン酸等の脂肪酸、グリセリンや１，３−ブタンジオール等の多価アルコール類、非イオン界面活性剤、アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、エタノール、カーボポール等の増粘剤、防腐剤、紫外線吸収剤、抗酸化剤、色素、粉体類等が例示できる。これらの上記抗真菌剤と任意成分とを常法に従って処理することにより、本発明の医薬組成物は製造することが出来る。
【００１７】
【化１９】

（化合物１）
【００１８】
【化２０】

（化合物２）
【００１９】
【化２１】

（化合物３）
【００２０】
【実施例】
以下に、実施例を挙げて、本発明について更に詳細に説明を加えるが、本発明がこれら実施例にのみ限定を受けないことは言うまでもない。
【００２１】
＜実施例１＞
Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物１）の合成
［工程Ａ］
Ｎ−（ｐ−ターシャリー−ブチルベンジル）メチルアミンの０．５ｇをＮ，Ｎ−ジメチルホルムアミド（以下、ＤＭＦ）１０ｍｌに溶解させ、炭酸ナトリウムを０．５ｇを混合し、これにＤＭＦ５ｍｌに２−ブロモ−３’（トリフルオロメチル）アセトフェノン０．７ｇを溶かした液を、室温で攪拌しながら滴下した。３時間攪拌した後、氷と飽和炭酸水素ナトリウム水溶液の上に、この反応液を一気に注いだ。酢酸エチル１００ｍｌで抽出し、炭酸水素ナトリウム水溶液、次いで飽和食塩水溶液で洗浄した。硫酸ナトリウムで乾燥した後、減圧濃縮し、シリカゲルカラムクロマトグラフィー（溶出溶媒；ｎ−ヘキサン：酢酸エチル＝１０：１）で精製し、化合物４を黄色油状物質として得た。（収率６９．４％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。（溶媒；ＣＤＣｌ₃、δｐｐｍ、以下に示すＮＭＲの数値は同様のものを示す。）
１．３１（ｓ，９Ｈ）、２．５３（ｓ，３Ｈ）、３．６３（ｓ，２Ｈ）、３．７３（ｓ，２Ｈ）、７．２４〜７．３５（ｍ，４Ｈ），７．５２〜７．８４（ｍ，２Ｈ）、８．１２〜８．３６（ｍ，２Ｈ）
【００２２】
［工程Ｂ］
ベンゼン１０ｍｌにメチルトリフェニルホスホニウムブロミド０．８ｇを懸濁させ、窒素雰囲気下室温で攪拌しながら、１．６３Ｍのｎ−ブチルリチウムヘキサン溶液１．４ｍｌを加えた。５分間攪拌した後、化合物４の０．４６ｇをベンゼン５ｍｌに溶かした液を滴下した。室温で１晩攪拌した後、氷水の上に注ぎ反応を止めた。これよりベンゼン１００ｍｌで抽出し、飽和食塩水で洗い、硫酸ナトリウムで乾燥させ、減圧濃縮し、これをシリカゲルカラムクロマトグラフィー（溶出溶媒；ヘキサン：酢酸エチル＝２０：１）で精製し、淡黄色の油状物質として化合物１を得た。（収率３３．２％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．１６（ｓ，３Ｈ）、３．３５（ｓ，２Ｈ）、３．４８（ｓ，２Ｈ）、５．３３（ｓ，１Ｈ）、５．５０（ｓ，１Ｈ）、７．１６（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）、７．３２（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）、７．４１（ｄｄ，１Ｈ，Ｊ＝７．８３Ｈｚ，７．８３Ｈｚ），７．５２（ｄ，１Ｈ，Ｊ＝７．８３）、７．６１（ｄ，１Ｈ，Ｊ＝７．８３Ｈｚ）、７．７３（ｓ，１Ｈ）
【００２３】
［工程Ｃ］
化合物１の０．０４ｇをイソプロピルエーテル５０ｍｌに溶解させ、室温で攪拌しながら４Ｎ−ＨＣｌ酢酸エチル溶液０．０４ｍｌを加えた。室温で一晩攪拌し後、析出した白色結晶を濾取し、乾燥させ、収率７３．２％で化合物１の塩酸塩を得た。このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．６０（ｄ，３Ｈ，Ｊ＝４．５９Ｈｚ）、３．９５〜４．２１（ｍ，４Ｈ）、５．９４（ｓ，１Ｈ）、６．０７（ｓ，１Ｈ）、７．４２〜７．６６（ｍ，８Ｈ）、１２．８（ｂｓ，１Ｈ）
【００２４】
又、融点は１７８．５〜１８２℃であり、赤外スペクトルは次に示すとおりである。（単位はｃｍ^-1）
３４２７、２９６９、２６９１、１４７６、１３９３、１３３９、１３０５、１２７１、１１６７、１１２８
【００２５】
＜実施例２＞
トランス−Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）−Ｎ−メチル−２−［３−（トリフルオロメチル）フェニル］−２−プロペニルアミン（化合物２）
実施例１の出発物質のＮ−（ｐ−ターシャリー−ブチルベンジル）メチルアミンをトランス−Ｎ−（６，６−ジメチル−２−ヘプテン−４−イニル）メチルアミンに変え、工程Ａを行い、化合物５を黄色油状物質として得た。（収率３４．８％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．２３（ｓ，９Ｈ）、２．３９（ｓ，３Ｈ）、３．２０（ｄｄ，２Ｈ，Ｊ＝１．３５Ｈｚ、６．７５Ｈｚ）、３．８０（ｓ，２Ｈ）、５．６６（ｔｄ，１Ｈ，Ｊ＝１．３５Ｈｚ、１７．３Ｈｚ）、６．０７（ｔｄ，１Ｈ，Ｊ＝６．７５Ｈｚ、１７．３Ｈｚ）、７．６０（ｄｄ，１Ｈ，Ｊ＝７．８３Ｈｚ、７．８３Ｈｚ）、７．８２（ｄ，１Ｈ，Ｊ＝７．８３Ｈｚ）、８．２１（ｄ，１Ｈ，Ｊ＝７．８３Ｈｚ）、８．３５（ｓ，１Ｈ）
【００２６】
この化合物５を実施例１の工程Ｂと同様の操作を行い、化合物２を得た。（収率１８．９％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．２４（ｓ，９Ｈ）、２．１８（ｓ，３Ｈ）、３．０４（ｄ，２Ｈ，Ｊ＝６．４８Ｈｚ）、３．３４（ｓ，２Ｈ）、５．３１（ｓ，１Ｈ）、５．５０（ｓ，１Ｈ）、５．６２（ｄ，１Ｈ，Ｊ＝１５．７Ｈｚ）、６．０３（ｔｄ，１Ｈ，Ｊ＝６．４８Ｈｚ、１５．７Ｈｚ）、７．４３（ｄｄ，１Ｈ，Ｊ＝７．５６Ｈｚ、８．１０Ｈｚ）、７．５２（ｄ，１Ｈ，Ｊ＝７．５６Ｈｚ）、７．６７（ｄ，１Ｈ，Ｊ＝８．１０Ｈｚ）
【００２７】
実施例１の工程Ｃと同様の操作を行い、化合物２の塩酸塩を作成した。（収率６０．１％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．２３（ｓ，９Ｈ）、２．６３（ｄ，３Ｈ，Ｊ＝４．８６Ｈｚ）、３．４９〜３．６３（ｍ，２Ｈ）、３．９８〜４．１９（ｍ，２Ｈ）、５．６９（ｄ，１Ｈ，Ｊ＝１５．７Ｈｚ）、６．２２（ｔｄ，１Ｈ，Ｊ＝７．２９Ｈｚ、１５．７Ｈｚ）、７．５４〜７．６７（ｍ，４Ｈ）、１３．０（ｂｓ，１Ｈ）
【００２８】
このもの融点は１６４〜１６５．５℃であり、赤外吸収スペクトルは次の通りである。（単位はｃｍ^-1）
３４４４、２９７３、２６２６、１３３７、１１６５、１１２９、１０７４
【００２９】
＜実施例３＞
Ｎ−（４−ターシャリー−ブチルベンジル）−Ｎ−メチル−２−（２，５−ジフルオロフェニル）−２−プロペニルアミン（化合物３）
実施例１の出発物質の２−ブロモ−３’−（トリフルオロメチル）アセトフェノンを２−ブロモ−２’，５’−ジフルオロアセトフェノンに変え、同様に工程Ａの処理して化合物６を黄色油状物質として得た。（収率３４．８％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．３６（ｓ，３Ｈ）、３．６８（ｓ，２Ｈ）、３．７９（ｄ，２Ｈ，Ｊ＝２．９７Ｈｚ）、７．０５〜７．１５（ｍ，２Ｈ）、７．１９（ｄ，２Ｈ，Ｊ＝８．６４Ｈｚ）、７．３０（ｄ，２Ｈ，Ｊ＝８．６４Ｈｚ）、７．４５〜７．５１（ｍ，１Ｈ）
【００３０】
この化合物６を実施例１の工程Ｂと同様の操作を行い、化合物３を得た。（収率１９．５％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．３０（ｓ，９Ｈ）、２．１５（ｓ，３Ｈ）、３．３３（ｓ，２Ｈ）、３．４５（ｓ，２Ｈ）、５．４１（ｓ，１Ｈ）、５．４９（ｓ，１Ｈ）、６．９２〜７．０４（ｍ，３Ｈ）、７．０８（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）、７．２８（ｄ，２Ｈ，Ｊ＝８．３７Ｈｚ）
【００３１】
実施例１の工程Ｃと同様の操作を行い、化合物３の塩酸塩を作成した。（収率９０．１％）このものの¹Ｈ−ＮＭＲは次に示すとおりである。
１．３１（ｓ，９Ｈ）、２．６３（ｄ，３Ｈ，Ｊ＝５．１３Ｈｚ）、３．８９〜４．２０（ｍ，４Ｈ）、５．８４（ｓ，１Ｈ）、６．１８（ｓ，１Ｈ）、６．８９〜７．１６（ｍ，３Ｈ）、７．４２（ｄ，２Ｈ，Ｊ＝８．９１Ｈｚ）、７．４６（ｄ，２Ｈ，Ｊ＝８．９１Ｈｚ）、１２．７（ｂｓ，１Ｈ）
【００３２】
このもの融点は１４５〜１４７℃であり、赤外吸収スペクトルは次の通りである。（単位はｃｍ^-1）
３４５４、２９６４、１４９３、１４６７、１４２５、１１８７
【００３３】
＜実施例４＞
抗菌性試験（発育阻止濃度の測定）
トリコフィトンに対する本発明の化合物の抗真菌作用を求めた。即ち、トリコフィトン・メンタグロファイテス（T.mentagrophytes TIMM1189）を予めサブロー寒天培地の斜面に２７℃で２週間培養して分生子を充分つくらせる。これをツィーン８０を０．０５重量／容量％含有する滅菌生理食塩水で白金耳で擦りながら洗浄し分生子を浮遊させる。これを二枚重ねのガーゼで濾過し分生子のみを生理食塩水に浮遊する形で取り出した。分生子の濃度を１０⁵個／ｍｌになるように調整し試験菌菌液とした。一方、化合物を４ｍｇとり、ジメチルスルホキサイド１ｍｌを加え原液とし、これを順次ジメチルスルホキサイドで２倍希釈し希釈薬剤液を調整した。組織培養用９６穴マイクロプレートの各ウェルにサブロー・デキストロース培地１７５μｌ、薬剤溶液５μｌ、試験菌菌液２０μｌを加え、良く混和した後、２７℃で１週間培養し目視にて完全に発育を阻止する最小濃度を探し、最小発育阻止濃度とした。結果は、化合物１の塩酸塩が３．１２μｇ／ｍｌであり、化合物２の塩酸塩が３．１２μｇ／ｍｌであり、化合物３の塩酸塩が０．２５μｇ／ｍｌであった。これより本発明の抗真菌剤の抗真菌作用が優れていることがわかる。
【００３４】
＜実施例５＞
下記に示す処方に従って本発明の医薬組成物である、水虫治療用の軟膏を作成した。即ち、処方成分をニーダーに秤込み混練りして軟膏を得た。
ワセリン ９９重量部
化合物１の塩酸塩 １重量部
【００３５】
＜実施例６＞
下記に示す処方に従って本発明の医薬組成物である、水虫治療用の軟膏を作成した。即ち、処方成分をニーダーに秤込み混練りして軟膏を得た。
ワセリン ９９重量部
化合物２の塩酸塩 １重量部
【００３６】
＜実施例７＞
下記に示す処方に従って本発明の医薬組成物である、水虫治療用の軟膏を作成した。即ち、処方成分をニーダーに秤込み混練りして軟膏を得た。
ワセリン ９９重量部
化合物３の塩酸塩 １重量部
【００３７】
【発明の効果】
本発明によれば、抗真菌作用を有する新規母核の化合物が提供できる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a novel fluorine-containing compound suitable for an antifungal agent.
[0002]
[Prior art]
Superficial mycosis, such as athlete's foot, has been overcome in the present age, because there are still no reliable treatments and drugs available, coupled with the fact that life has become westernized and shoe wear has increased. It is counted as one of the diseases that have not been done. Therefore, many compounds have been screened for antifungal activity. However, there are not many substances that have been found to be active in vitro or at the animal level but drop out in the actual clinical stage, and very few results have been obtained so far. That is, the discovery of a mother nucleus having a novel antifungal action has been awaited. This situation is not limited to superficial fungi, but amphotericin B, which is extremely toxic and has little effect on deep fungal diseases such as Candida albicans and Aspergillus niger, must be used. There is no extremely serious situation. That is, development of an antifungal agent having a novel mother nucleus has been desired.
[0003]
On the other hand, any of the compounds represented by the general formula (I) to be described later is a compound not described in any literature, and therefore it has not been known at all that such a compound has an excellent antifungal action.
[0004]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and an object of the present invention is to find a novel mother nucleus compound having an antifungal action.
[0005]
[Means for solving problems]
In view of such a situation, as a result of intensive research efforts to find a novel mother nucleus compound having antifungal activity, the present inventors have found that the compound represented by the general formula (I), particularly the general formula (II) ) And / or physiologically acceptable salts thereof have found such an action, and have completed the invention. Hereinafter, the present invention will be described in detail with a focus on embodiments.
[0006]
Embedded image

Formula (I)
(In the formula, R1 represents an aromatic hydrocarbon group containing a fluorine atom, R2 represents an alkyl group having 1 to 4 carbon atoms, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0007]
Embedded image

Formula (II)
(In the formula, X represents a fluorine atom or a trifluoromethyl group, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0008]
DETAILED DESCRIPTION OF THE INVENTION
(1) Compound represented by general formula (III) and / or general formula (IV) of the present invention The compound represented by general formula (III) and / or general formula (IV) of the present invention is represented by the general formula ( It is an important reaction intermediate in the preparation of compounds of I) and / or general formula (II). By subjecting this to the Wittig reaction, the compounds represented by the general formulas (I) to (II) of the present invention can be produced. In the present invention, among the compounds represented by the general formula (III), the compound of the general formula (IV) in which the side chain is specified is particularly preferable. As the halogen atom, a chlorine atom is particularly preferable. Also, as shown in Reaction Scheme 1, this compound is acetylated in the presence of a Lewis acid in the presence of an aromatic compound or its halide, and then the methyl hydrogen atom of this acetyl group is replaced with a halogen atom. It can be produced by condensation with an amine in the presence of an alkali. These compounds are all novel compounds not described in any literature. Particularly preferred as such a compound of the present invention is 2- [N- (4-tertiary-butylbenzyl) -N-methylamino] -3 ′-(trifluoromethyl) acetophenone (compound 4), Trans-2- [N- (6,6-dimethyl-2-hepten-4-ynyl) methylamino] -3 '-(trifluoromethyl) acetophenone (compound 5) and 2- [N- (4-tertiary) -Butylbenzyl) -N-methylamino] -2 ', 5'-difluoroacetophenone (compound 6).
[0009]
Embedded image

Formula (III)
(In the formula, R1 represents an aromatic hydrocarbon group containing a fluorine atom, R2 represents an alkyl group having 1 to 4 carbon atoms, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0010]
Embedded image

Formula (IV)
(In the formula, X represents a fluorine atom or a trifluoromethyl group, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0011]
Embedded image

(Compound 4)
[0012]
Embedded image

(Compound 5)
[0013]
Embedded image

(Compound 6)
[0014]
Embedded image

Reaction formula 1
(In the formula, X represents a fluorine atom or a trifluoromethyl group, and R3 represents a hydrocarbon group having at least 6 π electrons.)
[0015]
(2) Compounds represented by general formula (I) and general formula (II) of the present invention The compounds represented by general formula (I) and general formula (II) of the present invention are represented by the above general formula (III), It can be obtained by treating the compound represented by the general formula (IV) with methyltriphenylphosphonium bromide and butyl lithium, that is, subjecting it to a Wittig reaction. In the present invention, among the compounds represented by the general formula (I), a limited compound group represented by the general formula (II) is preferable. Furthermore, as a form of the fluorine atom, it is preferable to use the fluorine atom itself as a substituent or use a trifluoromethyl group as a substituent. This is because such a group of compounds has excellent antifungal activity. A specific example of such a compound is N- (4-tertiary-butylbenzyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 1). , Trans-N- (6,6-dimethyl-2-hepten-4-ynyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (compound 2), N- ( Examples include 4-tertiary-butylbenzyl) -N-methyl-2- (2,5-difluorophenyl) -2-propenylamine (Compound 3). These can be led to salts according to conventional methods. That is, a salt can be formed by adding a corresponding acid in an aqueous or non-aqueous solvent. Examples of preferred salts in the present invention include mineral acid salts such as hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid, and organic acid salts such as acetic acid, oxalic acid, maleic acid and fumaric acid. Is particularly preferred. This is because it is excellent in stability and economy. The compounds represented by the general formula (I) and / or the general formula (II) thus obtained and / or their salts can be used as the antifungal agent of the present invention because they have an excellent antifungal action. Moreover, since the antifungal agent of this invention is excellent also in safety, the administration route is not ask | required. The dose of the compound of the present invention as an antifungal agent varies depending on the patient's condition and symptoms. For example, in the case of oral administration or administration by injection, 1 to 10000 mg daily for adults may be once or several times. It is preferably administered separately, and if it is an external preparation for skin, it is preferable to apply an appropriate amount containing 0.1 to 10% by weight, and if it is a vaginal suppository, it contains 0.1 to 10% by weight. Is preferably administered once or several times.
[0016]
(3) Pharmaceutical composition of the present invention The pharmaceutical composition of the present invention is characterized by containing the antifungal agent of the present invention. As shown in the examples below, the antifungal agent of the present invention has an excellent antifungal action, so that the pharmaceutical composition of the present invention is used to treat superficial mycosis or deep mycosis, prevent deterioration, and relapse. It is very useful for prevention. Preferred examples of the pharmaceutical composition of the present invention include external preparations for skin such as liquids, creams and ointments, oral preparations such as tablets, capsules and powders, injections and vaginal suppositories. In addition to the above antifungal agents, the pharmaceutical composition of the present invention can contain optional components usually used in pharmaceutical compositions. Examples of such optional components include, for example, oral preparations and injections, excipients, binders, coating agents, lubricants, sugar coatings, disintegrating agents, extenders, flavoring agents, emulsification / solubilization. -Dispersants, stabilizers, pH adjusters, isotonic agents, etc. can be exemplified. For skin external preparations and vaginal suppositories, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax , Triglycerides such as beef tallow and olive oil, higher alcohols such as cetanol and oleyl alcohol, fatty acids such as stearic acid and oleic acid, polyhydric alcohols such as glycerin and 1,3-butanediol, nonionic surfactants, Examples include anionic surfactants, cationic surfactants, amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, dyes, powders, and the like. The pharmaceutical composition of the present invention can be produced by treating these antifungal agents and optional components according to a conventional method.
[0017]
Embedded image

(Compound 1)
[0018]
Embedded image

(Compound 2)
[0019]
Embedded image

(Compound 3)
[0020]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples, but it goes without saying that the present invention is not limited only to these examples.
[0021]
<Example 1>
Synthesis of N- (4-tertiary-butylbenzyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 1) [Step A]
0.5 g of N- (p-tertiary-butylbenzyl) methylamine is dissolved in 10 ml of N, N-dimethylformamide (hereinafter DMF), 0.5 g of sodium carbonate is mixed, and this is mixed with 5 ml of DMF. A solution in which 0.7 g of bromo-3 ′ (trifluoromethyl) acetophenone was dissolved was added dropwise with stirring at room temperature. After stirring for 3 hours, the reaction solution was poured all at once onto ice and saturated aqueous sodium hydrogen carbonate solution. The mixture was extracted with 100 ml of ethyl acetate and washed with an aqueous sodium hydrogen carbonate solution and then with a saturated saline solution. The extract was dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (elution solvent; n-hexane: ethyl acetate = 10: 1) to give compound 4 as a yellow oil. (Yield: 69.4%) ¹ H-NMR of this product is as shown below. (Solvent: CDCl ₃ , δ ppm, NMR values shown below are the same)
1.31 (s, 9H), 2.53 (s, 3H), 3.63 (s, 2H), 3.73 (s, 2H), 7.24 to 7.35 (m, 4H), 7 .52 to 7.84 (m, 2H), 8.12 to 8.36 (m, 2H)
[0022]
[Step B]
In 10 ml of benzene, 0.8 g of methyltriphenylphosphonium bromide was suspended, and 1.4 ml of a 1.63 M n-butyllithium hexane solution was added while stirring at room temperature under a nitrogen atmosphere. After stirring for 5 minutes, a solution prepared by dissolving 0.46 g of Compound 4 in 5 ml of benzene was added dropwise. After stirring overnight at room temperature, the reaction was stopped by pouring onto ice water. This was extracted with 100 ml of benzene, washed with saturated brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (elution solvent; hexane: ethyl acetate = 20: 1) to give a pale yellow Compound 1 was obtained as an oily substance. (Yield 33.2%) ¹ H-NMR of this product is as follows.
1.31 (s, 9H), 2.16 (s, 3H), 3.35 (s, 2H), 3.48 (s, 2H), 5.33 (s, 1H), 5.50 (s) , 1H), 7.16 (d, 2H, J = 8.37 Hz), 7.32 (d, 2H, J = 8.37 Hz), 7.41 (dd, 1H, J = 7.83 Hz, 7. 83 Hz), 7.52 (d, 1H, J = 7.83), 7.61 (d, 1H, J = 7.83 Hz), 7.73 (s, 1H)
[0023]
[Step C]
0.04 g of Compound 1 was dissolved in 50 ml of isopropyl ether, and 0.04 ml of 4N-HCl ethyl acetate solution was added with stirring at room temperature. After stirring at room temperature overnight, the precipitated white crystals were collected by filtration and dried to obtain the hydrochloride of compound 1 in a yield of 73.2%. ¹ H-NMR of this product is as follows.
1.31 (s, 9H), 2.60 (d, 3H, J = 4.59 Hz), 3.95 to 4.21 (m, 4H), 5.94 (s, 1H), 6.07 ( s, 1H), 7.42-7.66 (m, 8H), 12.8 (bs, 1H)
[0024]
Moreover, melting | fusing point is 178.5-182 degreeC and an infrared spectrum is as showing next. (Unit is cm ^-1 )
3427, 2969, 2691, 1476, 1393, 1339, 1305, 1271, 1167, 1128
[0025]
<Example 2>
Trans-N- (6,6-Dimethyl-2-hepten-4-ynyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 2)
The starting material N- (p-tertiary-butylbenzyl) methylamine of Example 1 was changed to trans-N- (6,6-dimethyl-2-hepten-4-ynyl) methylamine, and step A was performed. Compound 5 was obtained as a yellow oil. (Yield 34.8%) ¹ H-NMR of this product is as follows.
1.23 (s, 9H), 2.39 (s, 3H), 3.20 (dd, 2H, J = 1.35 Hz, 6.75 Hz), 3.80 (s, 2H), 5.66 ( td, 1H, J = 1.35 Hz, 17.3 Hz), 6.07 (td, 1H, J = 6.75 Hz, 17.3 Hz), 7.60 (dd, 1H, J = 7.83 Hz, 7. 83 Hz), 7.82 (d, 1H, J = 7.83 Hz), 8.21 (d, 1H, J = 7.83 Hz), 8.35 (s, 1H)
[0026]
This compound 5 was treated in the same manner as in step B of Example 1 to obtain compound 2. (Yield 18.9%) ¹ H-NMR of this product is as follows.
1.24 (s, 9H), 2.18 (s, 3H), 3.04 (d, 2H, J = 6.48 Hz), 3.34 (s, 2H), 5.31 (s, 1H) 5.50 (s, 1H), 5.62 (d, 1H, J = 15.7 Hz), 6.03 (td, 1H, J = 6.48 Hz, 15.7 Hz), 7.43 (dd, 1H, J = 7.56 Hz, 8.10 Hz), 7.52 (d, 1 H, J = 7.56 Hz), 7.67 (d, 1 H, J = 8.10 Hz)
[0027]
The same operation as in Step C of Example 1 was performed to prepare the hydrochloride of compound 2. (Yield 60.1%) ¹ H-NMR of this product is as shown below.
1.23 (s, 9H), 2.63 (d, 3H, J = 4.86 Hz), 3.49 to 3.63 (m, 2H), 3.98 to 4.19 (m, 2H), 5.69 (d, 1H, J = 15.7 Hz), 6.22 (td, 1H, J = 7.29 Hz, 15.7 Hz), 7.54 to 7.67 (m, 4H), 13.0 (Bs, 1H)
[0028]
Its melting point is 164-1655 ° C., and its infrared absorption spectrum is as follows. (Unit is cm ^-1 )
3444, 2973, 2626, 1337, 1165, 1129, 1074
[0029]
<Example 3>
N- (4-tertiary-butylbenzyl) -N-methyl-2- (2,5-difluorophenyl) -2-propenylamine (Compound 3)
The starting material 2-bromo-3 ′-(trifluoromethyl) acetophenone of Example 1 was changed to 2-bromo-2 ′, 5′-difluoroacetophenone and treated in the same manner as in step A to give compound 6 as a yellow oil Got as. (Yield 34.8%) ¹ H-NMR of this product is as follows.
1.31 (s, 9H), 2.36 (s, 3H), 3.68 (s, 2H), 3.79 (d, 2H, J = 2.97 Hz), 7.05 to 7.15 ( m, 2H), 7.19 (d, 2H, J = 8.64 Hz), 7.30 (d, 2H, J = 8.64 Hz), 7.45 to 7.51 (m, 1H)
[0030]
This compound 6 was subjected to the same operation as in step B of Example 1 to obtain compound 3. (Yield 19.5%) ¹ H-NMR of this product is as follows.
1.30 (s, 9H), 2.15 (s, 3H), 3.33 (s, 2H), 3.45 (s, 2H), 5.41 (s, 1H), 5.49 (s) , 1H), 6.92 to 7.04 (m, 3H), 7.08 (d, 2H, J = 8.37 Hz), 7.28 (d, 2H, J = 8.37 Hz)
[0031]
The same operation as in Step C of Example 1 was performed to prepare the hydrochloride of compound 3. (Yield 90.1%) ¹ H-NMR of this product is as shown below.
1.31 (s, 9H), 2.63 (d, 3H, J = 5.13 Hz), 3.89 to 4.20 (m, 4H), 5.84 (s, 1H), 6.18 ( s, 1H), 6.89 to 7.16 (m, 3H), 7.42 (d, 2H, J = 8.91 Hz), 7.46 (d, 2H, J = 8.91 Hz), 12. 7 (bs, 1H)
[0032]
Its melting point is 145 to 147 ° C., and its infrared absorption spectrum is as follows. (Unit is cm ^-1 )
3454, 2964, 1493, 1467, 1425, 1187
[0033]
<Example 4>
Antibacterial test (measurement of growth inhibitory concentration)
The antifungal action of the compounds of the present invention on trichophyton was determined. That is, Trichophyton mentagrophytes (T.mentagrophytes TIMM1189) is cultured in advance on a slope of Sabouraud's agar medium at 27 ° C. for 2 weeks to sufficiently produce conidia. This is washed with a sterilized physiological saline containing 0.05 wt / vol% of Tween 80 while rubbing with a platinum loop to float the conidia. This was filtered through two layers of gauze and only the conidia were taken out in a form floating in physiological saline. The concentration of conidia was adjusted to 10 ⁵ cells / ml to obtain a test bacterial cell solution. On the other hand, 4 mg of the compound was taken, and 1 ml of dimethyl sulfoxide was added to make a stock solution. Add 175 μl of Sabouraud dextrose medium, 5 μl of the drug solution, and 20 μl of the test bacterial solution to each well of a 96-well microplate for tissue culture, mix well, then incubate at 27 ° C. for 1 week to completely prevent growth. The minimum concentration was searched and used as the minimum growth inhibitory concentration. As a result, the hydrochloride of compound 1 was 3.12 μg / ml, the hydrochloride of compound 2 was 3.12 μg / ml, and the hydrochloride of compound 3 was 0.25 μg / ml. This shows that the antifungal action of the antifungal agent of the present invention is excellent.
[0034]
<Example 5>
An ointment for treating athlete's foot, which is a pharmaceutical composition of the present invention, was prepared according to the formulation shown below. That is, the prescription ingredients were weighed into a kneader and kneaded to obtain an ointment.
Petrolatum 99 parts by weight Compound 1 hydrochloride 1 part by weight
<Example 6>
An ointment for treating athlete's foot, which is a pharmaceutical composition of the present invention, was prepared according to the formulation shown below. That is, the prescription ingredients were weighed into a kneader and kneaded to obtain an ointment.
Vaseline 99 parts by weight Compound 2 hydrochloride 1 part by weight
<Example 7>
An ointment for treating athlete's foot, which is a pharmaceutical composition of the present invention, was prepared according to the formulation shown below. That is, the prescription ingredients were weighed into a kneader and kneaded to obtain an ointment.
Vaseline 99 parts by weight Compound 3 hydrochloride 1 part by weight
【The invention's effect】
According to the present invention, a novel mother nucleus compound having an antifungal action can be provided.

Claims (6)

N- (4-tertiary-butylbenzyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (Compound 1), trans-N- (6,6-dimethyl-2 -Heptene-4-ynyl) -N-methyl-2- [3- (trifluoromethyl) phenyl] -2-propenylamine (compound 2) or N- (4-tertiary-butylbenzyl) -N-methyl -2- (2,5-difluorophenyl) -2-propenylamine (compound 3) and / or physiologically acceptable salts thereof. An antifungal agent comprising the compound according to claim 1 and / or a physiologically acceptable salt thereof. The antifungal agent according to claim 2, wherein the fungus is a pathogen of foot and / or onychomycosis. A pharmaceutical composition comprising the antifungal agent according to claim 2 or 3 . 2- [N- (4-tert-butylbenzyl) -N-methylamino] -3 ′-(trifluoromethyl) acetophenone (compound 4), trans-2- [N- (6,6-dimethyl-2) -Heptene-4-ynyl) methylamino] -3 '-(trifluoromethyl) acetophenone (compound 5) or 2- [N- (4-tertiary-butylbenzyl) -N-methylamino] -2', 5'-difluoroacetophenone (Compound 6) . The method according to claim 1 compound according to claim 5 compounds according to, characterized in that subjected to Wittig reaction.